Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Market Growth 2023-2029

Global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Market Growth 2023-2029

Intravenous cytomegalovirus immunoglobulin (human) is used to prevent cytomegalovirus disease associated with kidney, lung, liver, pancreas, and heart transplantation. Prophylactic CMV-IGIV should be used in combination with ganciclovir in transplants of these organs other than the kidneys of CMV seropositive donors into seronegative recipients.

LPI (LP Information)' newest research report, the “Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) Industry Forecast” looks at past sales and reviews total world Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) sales in 2022, providing a comprehensive analysis by region and market sector of projected Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) sales for 2023 through 2029. With Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) industry.

This Insight Report provides a comprehensive analysis of the global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV).

The global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) players cover CSL, Biotest, Beijing Tiantan Biological Products, Taibang Biologic Group and Shanxi Kangbao Biological Product, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

This report presents a comprehensive overview, market shares, and growth opportunities of Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) market by product type, application, key manufacturers and key regions and countries.

Market Segmentation:

Segmentation by type
25 ml
50 ml
100 ml

Segmentation by application
Hopistial
Clinic
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
CSL
Biotest
Beijing Tiantan Biological Products
Taibang Biologic Group
Shanxi Kangbao Biological Product

Key Questions Addressed in this Report

What is the 10-year outlook for the global Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) market?

What factors are driving Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) market opportunities vary by end market size?

How does Cytomegalovirus Immune Globulin Intravenous Human (CMV-IGIV) break out type, application?

What are the influences of COVID-19 and Russia-Ukraine war?

Please note: The report will take approximately 2 business days to prepare and deliver.